Core Viewpoint - Baili Tianheng reported significant financial fluctuations in its Q3 2025 results, with a notable recovery in the third quarter after a challenging first nine months of the year [1] Financial Performance - For the period of January to September, the company achieved a revenue of 2.066 billion yuan, representing a year-on-year decline of 63.52% [1] - The net profit for the same period was -495 million yuan [1] - In Q3 alone, the company saw a remarkable revenue increase to 1.895 billion yuan, marking a year-on-year growth of 1625.08% [1] - The net profit for Q3 was 623 million yuan, indicating a turnaround from a loss of over 600 million yuan in the same quarter last year [1] Key Drivers - The revenue growth in Q3 was primarily attributed to the successful collaboration with BMS, particularly the achievement of a milestone in the global II/III phase key registration clinical trial IZABRIGHT-Breast01 on September 30 [1] - This milestone triggered the recognition of the first payment of 250 million USD under the collaboration agreement, contributing to the revenue for the period [1]

Core Viewpoint - Shuyou Shen (300204) has received acceptance from the Shenzhen Stock Exchange for its application to issue shares to specific investors, aiming to raise up to 1.253 billion yuan for innovative drug development and to supplement working capital [1][1][1] Group 1 - The company submitted its application for a private placement of shares on October 24 [1] - The Shenzhen Stock Exchange confirmed that the application documents were complete and decided to accept the application [1] - The intended fundraising amount is capped at 1.253 billion yuan [1]

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with revenue at 2.066 billion yuan, down 63.52% year-on-year, and a net profit loss of 495 million yuan, down 112.16% year-on-year [1] - In contrast, the third quarter showed a remarkable recovery, with revenue reaching 1.895 billion yuan, an increase of 1625.08% year-on-year, and a net profit of 623 million yuan, marking a turnaround from losses [1] - The increase in third-quarter revenue was attributed to the successful progress of a collaboration with BMS, which triggered a payment of 250 million USD due to the achievement of a milestone in a key clinical trial [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of 2.066 billion yuan, reflecting a year-on-year decrease of 63.52% [1] - The net profit for the same period was -495 million yuan, indicating a year-on-year decline of 112.16% [1] - In the third quarter alone, the company reported revenue of 1.895 billion yuan, which is a substantial year-on-year increase of 1625.08% [1] - The net profit for the third quarter was 623 million yuan, showing a significant recovery from previous losses [1] Strategic Developments - The company highlighted the successful advancement of its collaboration with BMS, which played a crucial role in the financial performance of the third quarter [1] - A key milestone in the global II/III phase clinical trial, IZABRIGHT-Breast01, was achieved on September 30, leading to the recognition of a payment under the collaboration agreement [1] - The payment of 250 million USD is expected to contribute positively to the company's revenue in the reporting period [1]

Core Viewpoint - The company has received notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance, which is subject to further review and approval by regulatory authorities [1] Group 1: Company Actions - The company announced that on October 24, 2025, it received a notice from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance [1] - The application documents submitted by the company were found to be complete by the Shenzhen Stock Exchange, leading to the decision to accept the application [1] Group 2: Regulatory Process - The stock issuance is contingent upon approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - There is uncertainty regarding whether the application will pass the review by the Shenzhen Stock Exchange and receive the necessary registration approval from the China Securities Regulatory Commission [1] Group 3: Investor Communication - The company will fulfill its obligation to disclose information in a timely manner based on the progress of this matter [1] - Investors are advised to pay attention to investment risks associated with this process [1]

舒泰神10月26日公告，公司于2025年10月24日收到深交所出具的《关于受理舒泰神（北京）生物制药股 份有限公司向特定对象发行股票申请文件的通知》，深交所对公司报送的向特定对象发行股票的申请文 件进行了核对，认为申请文件齐备，决定予以受理。公司本次向特定对象发行股票事项尚需通过深交所 审核，并获得中国证监会作出的同意注册的决定后方可实施。 ...

Core Viewpoint - The company received notification from the Shenzhen Stock Exchange regarding the acceptance of its application for a specific stock issuance, indicating a positive step towards capital raising [1] Group 1 - The company, Shuyou Shen (300204.SZ), announced that it received a notification from the Shenzhen Stock Exchange on October 24, 2025, regarding the acceptance of its application for issuing stocks to specific investors [1] - The Shenzhen Stock Exchange confirmed that the application documents submitted by the company were complete and decided to accept the application [1]

格隆汇10月26日丨舒泰神(300204.SZ)公布，公司于2025年10月24日收到深圳证券交易所(以下简称"深交 所")出具的《关于受理舒泰神(北京)生物制药股份有限公司向特定对象发行股票申请文件的通知》(深证 上审〔2025〕200号)，深交所对公司报送的向特定对象发行股票的申请文件进行了核对，认为申请文件 齐备，决定予以受理。 ...

Core Viewpoint - The company, Shuyou Shen (300204.SZ), announced plans to issue shares to specific investors, aiming to raise a total of no more than 1.253 billion yuan for innovative drug research and development projects, as well as to supplement working capital [1] Group 1 - The total amount to be raised through the share issuance is capped at 1.253 billion yuan [1] - The funds will be allocated for innovative drug research and development projects [1] - Additional funds will be used to supplement the company's working capital [1]

Group 1 - The core point of the article is that *ST Bio reported its third-quarter performance, showing a decline in revenue but a significant increase in net profit and earnings per share [1] Group 2 - For the third quarter of 2025, *ST Bio's revenue was approximately 83.44 million yuan, a year-on-year decrease of 9.72% [1] - The net profit attributable to shareholders was about 5.23 million yuan, reflecting a year-on-year increase of 162.21% [1] - The basic earnings per share were 0.0159 yuan, which is an increase of 162.35% compared to the previous year [1] - As of the report, *ST Bio's market capitalization stood at 3.1 billion yuan [2]

智通财经APP讯，申联生物(688098.SH)披露2025年第三季度报告，公司前三季度实现营收2.38亿元，同 比下降4.27%;归母净利润28万元，同比扭亏为盈;扣非净利润亏损510万元;基本每股收益0元。 ...